AMSTERDAM (August 18, 2022)—Royal Philips, a global provider of health technology, announced that Roy Jakobs is proposed to succeed Frans van Houten as president and chief executive officer, effective Oct. 15, 2022.
The supervisory board and van Houten have agreed that with the end of his third term in sight, the time is right for the change in leadership. After a comprehensive evaluation of external and internal candidates, the supervisory board has unanimously decided to propose Jakobs as the next president and CEO of Royal Philips to its general meeting of shareholders.
Jakobs brings a strong international, operational and transformational track record, as well as a deep understanding of Philips, which is critical at this important juncture in the company's growth journey. Jakobs has been successful in turning around businesses in customer-focused growth organizations and has effectively strengthened the company’s Connected Care portfolio through successful acquisitions across hospital and ambulatory care settings. Since taking on responsibility for the voluntary recall notification/field safety notice for specific Respironics devices on behalf of Philips, substantial progress has been made under his leadership in the execution of the comprehensive program aimed at delivering a resolution to affected patients as fast as possible in consultation with the relevant competent authorities.
"On behalf of the entire supervisory board, I would like to thank Frans for his transformational leadership of Philips over the last nearly 12 years,” said Feike Sijbesma, chairman of the supervisory board of Royal Philips. “Guided by his vision and the execution of the strategic roadmap, he has successfully led the company’s transformation from a diversified industrial conglomerate into a focused, global solutions leader in health technology. Building on its 131-year heritage, he repositioned Philips to significantly enhance the future value-creating prospects of the company. Frans led Philips with genuine care for its customers, patients, and its employees.”
An extraordinary general meeting (EGM) of shareholders will be held on Sept. 30, 2022, to appoint Jakobs as president and CEO, effective Oct. 15, 2022. van Houten will act as an advisor to the company—supporting the transition—until April 30, 2023.
"It has been both a privilege and a pleasure to lead the transformation of Philips, over the past 12 years, into one of the largest health technology companies in the world, bringing innovative solutions to help our customers deliver on the Quadruple Aim of better health outcomes, higher healthcare productivity and much improved patient and staff experience,” said van Houten, CEO of Royal Philips. “I have very much enjoyed working with so many talented and committed colleagues and building long-term relationships with our customers and other stakeholders. While I am proud of our many accomplishments, much remains to be done to enhance the resilience of Philips to manage through current setbacks and adverse market conditions. I gladly hand over to my executive committee team member Roy Jakobs in the knowledge that he brings the experience, energy, and commitment to take Philips on the path forward, with continuity for our customers and determination to improve the health and well-being of billions of people in a sustainable and responsible way. I wish Roy every success over the coming years and will support him as much as I can along the way.”
"I am delighted to have the opportunity to lead Philips to improve people’s health and well-being through innovation,” said Jakobs. “I aim to build on the company’s strong foundation as a purpose-driven health technology leader with deep innovation and clinical expertise, to serve the needs of patients and consumers today and in the future. I look forward to working with Philips’ teams across the world to deliver a strong value creation trajectory for shareholders and all our other stakeholders. I also want to take this opportunity to thank Frans for his trust and the great support he has given me over the years.”
In close cooperation with Sijbesma and the supervisory board, Jakobs will further improve and strengthen Philips’ performance as a leading health technology company with a planned approach. Key priorities are to further deepen the quality and patient safety capability across the company, complete the Respironics field action in consultation with the relevant competent authorities, and lead Philips to resume its profitable growth trajectory by addressing current headwinds, including strengthening supply chain resilience to enable the successful conversion of the all-time-high order book into sales.
Visit philips.com for more information.
